The Wells Fargo 21st Annual Healthcare Conference handed managed care traders two very different headlines over 48 hours. Elevance Health (ELV) surged nearly 6% Thursday after CFO Mark Kaye told the audience that Q3 adjusted EPS is running ahead of the outlook issued after Q2 results. UnitedHealth (UNH) fell about 3% Wednesday after Bloomberg reported that TPG is buying an interest in some of its Florida WellMed clinics, even as management simultaneously reaffirmed full-year guidance.
Elevance: The Quarter Is Ahead of Plan
Elevance stock surged above $418 intraday after the company filed a Regulation FD disclosure reaffirming full-year 2026 adjusted EPS guidance of at least $27.00, and signaled at the Wells Fargo conference that Q3 adjusted EPS is tracking ahead of the outlook it provided after Q2 results. The intra-quarter update cited favorable benefit expense performance as a key driver, giving investors a meaningful positive data point well ahead of the next scheduled earnings release.
Management also said 2026 should be the trough year for Medicaid margins, with improvement expected in 2027 as rates better match costs. The company is targeting at least 12% adjusted EPS growth in 2027 from the 2026 baseline, supported by multiple businesses rather than a single segment. ELV’s next earnings date is October 21, which gives traders several weeks to position around that Q3 confirmation. The key watch: whether benefit expense trends hold as the quarter closes out.
UnitedHealth: Guidance Holds, Clinics Sold
UnitedHealth sold an interest in its Florida WellMed primary-care clinics to TPG, Bloomberg reported September 9. The clinics sit inside Optum Health, UnitedHealth’s care-delivery arm. Neither company disclosed financial terms. UnitedHealth CFO Wayne DeVeydt called the arrangement a growth partnership rather than a capital raise.
The guidance reaffirmation is the more meaningful near-term catalyst, since the July 16 update lifted UnitedHealth’s full-year adjusted EPS to $19.50 to $20.00 and raised cash flows from operations guidance to about $24 billion. Medicare Advantage margins are tracking to the upper half of the company’s 2% to 4% target range, and trend durability seen in Q1 and Q2 has continued into the first two months of Q3. That is the strongest piece of the UNH presentation: the MA margin signal matters more to the 2027 outlook than the WellMed transaction.
The broader healthcare ETF XLV dropped about 0.4% and peers ELV and HUM held steady, confirming the selloff was UNH-specific rather than a sector-wide story. The slide came even as UnitedHealth stock was up about 19% year to date as of September 9.
What Traders Watch Today
- ELV: Conference-week momentum with a Q3 beat already telegraphed. Resistance near the 52-week high at $436. Any pullback toward $400 extends the risk/reward.
- UNH: Analyst consensus for full-year 2026 adjusted EPS sits around $19.81, inside management’s range. A clean reaffirmation keeps those numbers intact; any hedging language on Optum Health could reopen the debate the WellMed deal is meant to settle.
- Sector read-through: HUM, CI, and CVS did not crack on the UNH noise. That relative strength is worth tracking if managed care continues to recover into Q3 reporting season starting in mid-October.
The Cheat Sheet
Top Theme: Managed care is resetting higher at the conference level, with ELV leading and UNH digesting its clinic deal.
Stock to Watch: ELV. The Q3 signal is explicit and the stock is below its 52-week high with a confirmed earnings tailwind.
Biggest Risk: UNH’s WellMed disclosure had no financial terms attached. If terms surface and the valuation looks unfavorable, the dip could deepen.
One Thing to Remember: Managed care has already had a big run since late 2025, so the sector is no longer cheap. Catalyst quality matters more than sector momentum from here.
